Payment overview · 2025
General Payments
$1,560.89
63 reported records · 27 companies
Healthcare provider profile · identity verified
Diane S Knapp, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · BEAVER, PA · NPI 1912090499
Verified facts
What the public records show
CMS Open Payments records show Diane S Knapp, CRNP received $1,560.89 in general payments during 2025 across 63 reported records.
Amneal Pharmaceuticals LLC accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta, Unithroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UNITHROID as an associated drug or biological on 7282 records involving 3230 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Unithroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $274.07 | 17.6% | 10 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $114.19 | 7.3% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $105.29 | 6.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $103.84 | 6.7% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$89.02 | 5.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $80.05 | 5.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $78.29 | 5.0% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $76.87 | 4.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $61.51 | 3.9% | 3 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $57.33 | 3.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $56.88 | 3.6% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $52.64 | 3.4% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $45.25 | 2.9% | 2 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $40.82 | 2.6% | 2 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $29.16 | 1.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $29.14 | 1.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $28.94 | 1.9% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $26.04 | 1.7% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.43 | 1.6% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $25.25 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.91 | 1.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.18 | 1.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.42 | 1.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.93 | 1.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.44 | 1.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.32 | 1.4% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $20.68 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,560.89 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $274.07 | 10 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $89.02 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $82.83 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $80.05 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $78.29 | 3 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $57.33 | 2 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $53.36 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $52.64 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $51.43 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.48 | 2 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $45.25 | 2 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $40.82 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.84 | 2 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $29.16 | 1 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $29.14 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $28.94 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $26.04 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $25.44 | 1 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $25.43 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $25.25 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.18 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 22 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UNITHROID unithroid |
2025 | Unithroid | 2024 | 28 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | 11 |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | UNITHROID open payments reported associated product |
CMS Open Payments — General Payments 7282 supporting records · 3230 recipient NPIs · example record 1220525525 |
Unithroid · 2024 Exact normalized brand match · 1 Part D row |
28 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 59 | 39 |
| Ezetimibe | Ezetimibe | 58 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 42 | 30 |
| Metformin Hcl Er | Metformin Hcl | 41 | 28 |
| Montelukast Sodium | Montelukast Sodium | 40 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 28 |
| Lisinopril | Lisinopril | 31 | 22 |
| Omeprazole | Omeprazole | 31 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | 18 |
| Unithroid | Levothyroxine Sodium | 28 | 12 |
| Ozempic | Semaglutide | 27 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | 17 |
| Azithromycin | Azithromycin | 23 | 19 |
| Jardiance | Empagliflozin | 22 | 12 |
| Synthroid | Levothyroxine Sodium | 21 | 11 |
| Amlodipine Besylate | Amlodipine Besylate | 19 | 15 |
| Furosemide | Furosemide | 19 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Famotidine | Famotidine | 17 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 16 | 11 |
| Metformin Hcl | Metformin Hcl | 16 | suppressed |
| Gabapentin | Gabapentin | 14 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | 13 |
| Losartan Potassium | Losartan Potassium | 14 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | 11 |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,560.89 · 63 records | Amneal Pharmaceuticals LLC | BREZTRI, CRENESSITY, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, GIMOTI, GVOKE HYPOPEN, ISTURISA, JARDIANCE, Kerendia, Korlym, MINIMED 780G, MOUNJARO, NEXLETOL, NURTEC ODT, Omnipod, Ozempic, PAXLOVID, QUTENZA, RECORLEV, REPATHA, REZDIFFRA, STRENSIQ, TEPEZZA, TRELEGY ELLIPTA, TWIIST, UBRELVY, UNITHROID, Veozah, Yorvipath | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error